These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 18195140)

  • 1. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
    Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
    AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
    Marra CM
    Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients.
    Ances BM; Roc AC; Korczykowski M; Wolf RL; Kolson DL
    J Neurovirol; 2008 Oct; 14(5):418-24. PubMed ID: 19040188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
    Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
    Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
    Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
    J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
    Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
    Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Caniglia EC; Cain LE; Justice A; Tate J; Logan R; Sabin C; Winston A; van Sighem A; Miro JM; Podzamczer D; Olson A; Arribas JR; Moreno S; Meyer L; del Romero J; Dabis F; Bucher HC; Wandeler G; Vourli G; Skoutelis A; Lanoy E; Gasnault J; Costagliola D; Hernán MA;
    Neurology; 2014 Jul; 83(2):134-41. PubMed ID: 24907236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
    De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
    Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
    Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
    Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.
    Arentoft A; Troxell K; Alvarez K; Aghvinian M; Rivera Mindt M; Cherner M; Van Dyk K; Razani J; Roxas M; Gavilanes M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
    Marra CM; Maxwell CL; Collier AC; Robertson KR; Imrie A
    BMC Infect Dis; 2007 May; 7():37. PubMed ID: 17475004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.